FDG-PET in oncology: Techniques and applications [FDG-PET in der onkologie. Methodische grundlagen und klinische anwendung]

被引：0

作者：

Kletter K. ^{[1
]}

Becherer A. ^{[1
]}

机构：

[1] Klinik für Nuklearmedizin, Währinger Gürtel 18-20

来源：

Der Radiologe | 1999年 / 39卷 / 7期

关键词：

18F-fluorodeoxyglucose; Clinical application; Oncology; PET;

D O I：

10.1007/s001170050556

中图分类号：

学科分类号：

摘要：

Clinical PET is now primarily used in oncological indications. Fluorine- 18-fluorodeoxyglucose (FDG) shows a high uptake in a variety of malignancies and accounts for approximately 95% of the oncological PET studies. The first part of this review deals with theoretical and methodological aspects of FDG- PET. Possible sources of errors for the method are discussed briefly. Oncological indications for FDG-PET are highlighted according to the results of consensus meetings of experts from nuclear medicine and oncology, organized by the German Society of Nuclear Medicine. FDG-PET is mainly used in staging and restaging, demonstrating of tumour recurrence and therapy control. Main benefits of the method are functional imaging, better spatial resolution than conventional scintigraphy and the possibility to perform whole-body imaging easily. A brief outlook on future prospects for the application of PET in oncology is given.

引用

页码：600 / 609

页数：9

共 30 条

[1]

Adams, S., Baum, R.B., Stuckensen, T., Bitter, K., Hör, G., Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT,MRI,US) in lymph node staging of head and neck cancer (1998) Eur J Nucl Med, 25, pp. 1255-1260

[2]

Konsensus-Onko-PET (1997) Nuklearmedizin, 36, pp. 45-46

[3]

Chiti, A., Schreiner, F.A.G., Crippa, F., Pauwels, E.K.J., Bombardieri, E., Nuclear medicine procedures in lung cancer (1999) Eur J Nucl Med, 26, pp. 533-555

[4]

Cook, G.J.R., Fogelman, I., Maisey, M.N., Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: Potential for error in interpretation (1996) Semin Nucl Med, 26, pp. 308-314

[5]

De, W., Bumann, D., Beyer, W., Herbst, K., Clausen, M., Hossfeld, D.K., Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma (1997) Ann Oncol, 8 (SUPPL. 1), pp. 57-60

[6]

Delbeke, D., Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lyphoma and melanoma (1999) J Nucl Med, 40, pp. 591-603

[7]

Delbeke, D., Vitola, J.V., Sandler, M.P., Arildsen, R.C., Powers, T.A., Wright J.K., Jr., Chapman, W.C., Pinson, C.W., Staging recurrent metastatic colorectal carcinoma with PET (1997) J Nucl Med, 38, pp. 1196-1201

[8]

Dewan, N.A., Gupta, N.C., Redepenning, L.S., Phalen, J.J., Frick, M.P., Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules (1993) Chest, 104, pp. 997-1002

[9]

Feine, U., Lietzenmayer, R., Hanke, J.P., Held, J., Wöhrle, H., Müller-Schauenburg, W., Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer (1996) J Nucl Med, 37, pp. 1468-1472

[10]

Flier, J.S., Mueckler, M.M., Usher, P., Lodish, H.F., Elevated levels of glucose transport and transporter messenger RNA are induced by rats or src oncogenes (1987) Science, 235, pp. 1492-1495

← 1 2 3 →